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L
ung function has been one of the most important assessment tools available to investigators of the health effects of air pollution. Although some measurements of lung function require sophisticated equipment, basic lung function parameters can be measured with spirometers. Whereas there is no question that lung function in children is decreased on exposure to particulate matter air pollution (PM), [1] [2] [3] [4] [5] the situation in adults in not quite as clear.
Nevertheless, there are some studies that document such a relationship. Both FEV 1 and peak expiratory flow (PEF) have been used to assess the effects on lung mechanics from exposure to PM. For instance, Grievink and associates 6 studied a panel of adults in Europe with chronic respiratory disease and reported decrements in PEF. Van der Zee and coworkers 7 studied a large cohort of adult subjects aged 50 to 70 years both with and without chronic respi-ratory disease over a period of three winters. Fairly large decrements were reported per 100 g/m 3 PM Յ 10 m in diameter (PM 10 ) in morning PEF measured on the same day lag as outdoor air pollutants. Brauer and colleagues 8 reported an association between lung function and personal exposure to PM in a panel study of subjects with COPD in Vancouver, BC. Although not significant, decrements of 3% and 1% in FEV 1 were associated with PM 10 or PM Յ 2.5 m in diameter (PM 2.5 ), respectively. In a study from Finland, Penttinen et al 9 reported that both the number concentration and the size of particles (0.1 to 1 m) were determinants of associations between PM and decreased lung function. However these associations were mainly nonsignificant. The number of accumulation mode particles was consistently inversely associated with PEF in a group of 78 adult subjects with asthma. We have reported associations between PM 2.5 and decrements in lung function (1.8-mL decrement in FEV 1 per 1 g/m 3 PM 2.5 ) 10 and symptom exacerbation 11 in children with asthma in Seattle.
Current research is focused on understanding better the identification of susceptible populations and differentiating personal, indoor, and outdoor exposure from central site exposures. There is some concern that pollutants measured at central sites do not represent individual or residential community exposures. In this article, we present data on relationships between lung function changes in both adults and children over 5-to 10-day monitoring periods during which daily PM was measured outside, inside, and on the person in Seattle.
Materials and Methods
We performed a 3-year panel study (from 1999 to 2002) in Seattle that evaluated cardiac and respiratory effects of personal, indoor, and outdoor measures of air pollution in 57 elderly subjects who were either healthy or had respiratory or cardiac disease. We also studied 17 children with asthma. The experimental design and exposure monitoring methods are described below. A detailed discussion of the exposure assessment methods and results has been published previously. 12 Subjects were recruited through distribution of advertisements at clinics, senior centers, and retirement homes. All but one of the adult subjects was Ͼ 65 years of age; 85% were between 71 years and 90 years of age. The children were 6 to 13 years of age. Many of the subjects (55%) enrolled for more than one monitoring period (session). The inclusion criteria for the adult subjects with respiratory disease were physician-diagnosed COPD and FEV 1 between 30% and 70% of predicted. Because of the high incidence of hypertension in normal elderly subjects, those with hypertension were not excluded from the adult group, which also included subjects with a history of myocardial infarction or angina. All subjects were nonsmokers and lived with nonsmokers. The children all had physician-diagnosed asthma and were recruited from a large asthma and allergy clinic. Since children with asthma experience small airway inflammation in response to extrinsic triggers, 13, 14 maximal midexpiratory flow (MMEF) was added as a potentially more sensitive (than FEV 1 or PEF) indicator of small airway function.
Personal, indoor, and outdoor monitoring was conducted for all subjects. PM 2.5 and PM 10 gravimetric 24-h measurements were obtained inside and outside subjects' residences with single-stage inertial Harvard impactors operated at a flow rate of 4 L/min (Air Diagnostics and Engineering; Naples, ME). 15 Each subject also carried a personal monitor (Harvard Personal Environmental Monitor for PM 2.5 ; Harvard School of Public Health; Boston, MA) for 24 h each day, which was worn or placed close to the person. These integrated fixed-site and personal measurements were collected over 24 h for 5 to10 consecutive session days. Exposure monitoring began 1 day prior to health measurements to provide 24-h exposure data to help compensate for lag structure. Subjects were monitored during 26 exposure sessions: Lung function measurements in adults were collected using portable spirometers (VM Plus; Clement Clarke; Columbus, OH) that record both FEV 1 and PEF, consisting of a modified Mini-Wright peak flowmeter and standard mouthpiece. The spirometers were calibrated with a 3-L syringe at the beginning of each 10-day session. Lung function measurements in the children (FEV 1 , PEF, MMEF) were also collected using spirometers (MicroDL; Micro Direct; Lewiston, ME). Lung function maneuvers were collected according to American Thoracic Society guidelines. 16 Lung function data not conforming to American Thoracic Society within-test reproducibility criteria were excluded. Subjects were instructed to withhold use of bronchodilator medications within 4 h of the scheduled technician visit. Technicians coached the subjects in spirometric maneuvers once a day during the daily visit to subjects' residences. All subjects completed daily symptom and medication-use diaries.
Mixed-effects random intercept longitudinal regression models were applied to test for decreases in lung function associated with a 10 g/m 3 increase in exposure. Nested random intercepts were included to accommodate variation in susceptibility among subjects (a subject-specific random intercept) as well among sessions within subjects (a subject-session specific random intercept). Pulmonary function and exposure measurements were analyzed using SAS software (Proc Mixed; SAS Institute; Cary, NC). Seasonal confounding is a major concern when subjects are observed during different times of the year. In addition to controlling for climatologic covariates, we controlled for seasonal confounding by decomposing daily PM 2.5 concentrations into three components: let Xisd be a PM 2.5 exposure measure for subject i on day d of session s. Then Xisd ϭ Xi ϩ (XisXi) ϩ (Xisd -Xis). Xi is subject i's average exposure during the time he or she was observed, Xis -Xi is the difference between his or her average during session s and his or her overall average exposure, and Xisd -Xis is the difference between his or her daily exposure on day d of session s and his or her average exposure during session s. When modeling, we included all three components as separate covariates; however, we believe that the first two are confounded by season, and we do not interpret parameters associated with them. We believe Xisd Ϫ Xis is less confounded by season, and the parameter associated with it is our estimation target. We interpret the parameter estimate as the expected response change (in lung function) for short-term changes in PM 2.5 concentrations. Additional control was made for temperature, relative humidity, age, gender, and body mass index (BMI) for children. COPD status and its interaction term were included for the adults, and antiinflammatory medication status and its interaction term were included for children. A sensitivity analysis including daily co-pollutants (carbon monoxide and nitrogen dioxide) was evaluated. Parameter estimates corresponding to PM covariates were combined using standard procedures. 17, 18 
Results

Adult Subjects
A total of 57 subjects (24 with COPD and 33 without COPD) were included in this analysis. The COPD subjects ranged in age from 65 to 89 years; non-COPD subjects were 56 to 88 years old. The median age for both groups was 76 years. Many of the subjects (33%) enrolled for more than one session (10-day monitoring period). The median percentage of predicted FEV 1 at screening for the subjects was 56% for COPD subjects and 100% for non-COPD subjects. The percentage of predicted FEV 1 value for two subjects with COPD at screening was Ͼ 75% and for one COPD subject was Ͻ 30%. Subjects were stratified into those with and without COPD. Subject characteristics and outcome variables are shown in Table 1 .
Median 24-h PM 2.5 values from three central sites in Seattle representative of the residential area in this study were 10.3 g/m 3 (207 days). Median 24-h PM 2.5 values outside subjects' residences were 8.6 g/m 3 (646 subject days). Median indoor 24-h PM 2.5 values were 7.6 g/m 3 (649 subject days). Median personal 24-h PM 2.5 values were 8.5 g/m 3 (596 subject days). In this study, we observed strong correlations (r ϭ 0.70) between home outdoor and central site PM 2.5 measurements, similar to those previously reported for the larger panel study. 12, 19 Exposure distributions of outdoor PM 2.5 by subject session (10-day monitoring period) are given in Table 2 .
Our primary analyses assessed associations between change in lung function (FEV 1 or PEF) and personal, indoor, outdoor, and central site PM 2.5 and outdoor coarse fraction of PM. In the initial analysis, there were not any associations among these variables, with the one exception of a positive association with coarse fraction in subjects without COPD (data not shown). We also performed a sensitivity analysis that added two outdoor gaseous air pollutants to the model, CO and NO 2 . In this analysis, associations between decreases in FEV 1 and central site PM 2.5 were observed overall for same-day and 1-day lagged (Ϫ 35.5 mL; 95% confidence interval [CI], Ϫ 70.0 to Ϫ 1.0; and Ϫ 40.4 mL; 95% CI, Ϫ 71.1 to Ϫ 9.6, respectively) and in the COPD group (Ϫ 70.8 mL; 95% CI, Ϫ 118.4 to Ϫ 23.1) for 1-day lagged exposure. The 1-day lagged outdoor PM 2.5 associations with FEV 1 , although not statistically significant, showed the strongest COPD interaction effect. No associations between PEF and PM exposure were observed for adult subjects (Table 3) .
Pediatric Subjects With Asthma
Demographic and descriptive data for the 17 study subjects are listed in Table 1 . Median age of subjects was 9 years (range, 6 to 12 years), with 13 male and 4 female subjects participating. Ages were comparable in medication groups, although a larger percentage of male subjects were in the antiinflammatory medication-use group. Eleven subjects were prescribed antiinflammatory medication that included inhaled corticosteroids (n ϭ 7), leukotriene inhibitors (n ϭ 3), and a combination of inhaled corticosteroids and leukotriene inhibitors (n ϭ 1). Of the six subjects not prescribed antiinflammatory medications, one reported use of extended bronchodilators and the remainder used bronchodilators regularly or as needed. Most study subjects had mild persistent asthma as indicated by the use of daily antiinflammatory control medication and normal baseline FEV 1 .
Daily air pollution and meteorologic measurements are presented in Table 2 . Median 24-h PM 2.5 values from three central sites in the Seattle area were 11.2 g/m 3 (98 days). Median 24-h PM 2.5 values outside subjects' residences were 9.6 g/m 3 (291 subject days). Median indoor 24-h PM 2.5 values were 7.5 g/m 3 (296 subject days). Median personal 24-h PM 2.5 values were 11.3 g/m 3 (263 subject days). Session-specific outdoor PM levels are presented in Figure 1 . In this study, we observed strong correlations (r ϭ 0.77) between home outdoor and central site PM 2.5 measurements. 12, 19 Results of tests for associations between pediatric spirometric measures (MMEF, PEF, FEV 1 ) and PM metrics are presented in Table 4 . These analyses included adjustment for CO and NO 2. Same-day PM 2.5 measured at indoor, outdoor, and central sites was significantly associated with declines in MMEF among pediatric subjects with asthma who were not prescribed antiinflammatory medications (97 observations from 11 subject sessions, n ϭ 6). Same-day indoor PM 2.5 was associated with a 45.9-mL decrease in FEV 1 overall, with a stronger association in the no-antiinflammatory medications group (Ϫ 75.9 mL). PEF decrements were significantly associated with indoor PM 2.5 (same day and lagged) both overall and in the no-antiinflammatory medications group. Personal 1-day lagged PM 2.5 was associated with a 10.5 L/min decrement in PEF, which contributed to a significant interaction between personal PM 2.5 and medication group (p ϭ 0.02). Indoor results for MMEF in the no-antiinflammatory medications group are consistent with those for PEF, while same-day outdoor and central site PM 2.5 decrements for MMEF are stronger than those for PEF. The medication group and PM 2.5 interactions are greater for MMEF than PEF.
In the analysis that did not control for CO and NO 2 (data not shown), same-day indoor PM 2.5 was associated with a 69.3-mL decrease in FEV 1 (95% CI, Ϫ 137.0 to Ϫ 1.82) among subjects in the noantiinflammatory medications group; there were comparable decrements in FEV 1 associated with 1-day lagged indoor PM 2.5 for all groups. Decrements in PEF were observed in the non-antiinflammatory medication group for same day and 1-day lagged indoor (Ϫ 12.3 L/min; 95% CI, Ϫ 24.6 to Ϫ 0.1; and Ϫ 15.6 L/min; 95% CI, Ϫ 28.2 to Ϫ 3.1, respectively), and 1-day lagged personal (Ϫ 9.9 L/min; 95% CI, Ϫ 18.0 to Ϫ 1.8) PM 2.5 exposure. These associations were not observed for subjects prescribed antiinflammatory medications. Significant declines in MMEF were observed overall (Ϫ 10.5 L/min; 95% CI, Ϫ 15.4 to Ϫ5.7) and in both medication categories for 1-day lagged indoor PM 2.5 measurements. The largest decrement (Ϫ 13.7 L/min; 95% CI, Ϫ 21.4 to Ϫ 5.9) was in the group not prescribed antiinflammatory medications.
For both MMEF (indoor, outdoor, central site) and PEF (personal), there was a significant interaction by antiinflammatory medication category, which was not significant for FEV 1 . That is, the estimated negative effects of PM on MMEF and PEF were significantly stronger in the group without antiinflammatory medication than in the group with such medication. There were no significant associations for derived outdoor coarse fraction and lung function changes (with or without controlling for CO and NO 2 ). Some stronger associations were observed in the analysis controlling for centrally measured CO and NO 2 . These included a significant overall effect between PEF, FEV 1 , and same-day indoor PM 2.5 measurements, as well as between PEF and 1-day lagged indoor PM 2.5 . However, controlling for gases weakened the overall association for MMEF and the *Data are presented as mean (95% CI)/No. of subject days. PM 2.5 exposure was decomposed into three components: (1) each subject's overall mean, (2) the difference between each subject's session-specific mean and his or her overall mean, and (3) the difference between subjects' daily values and the session-specific mean. All three were modeled though coefficients reported correspond to the parameter associated with (3). We controlled for gender, age, central site temperature and relative humidity, CO, and NO medication group associations for 1-day lagged indoor PM 2.5 , although the overall association remained significant for FEV 1 .
Discussion
This study found decrements in lung function associated with PM exposure in both elderly adults with COPD and children with asthma. Associations were strongest for central site PM 2.5 and FEV 1 in adults with COPD. PEF results in this group are consistent with those for FEV 1 , but the association is weaker. Unfortunately, the association between PM and MMEF could not be tested in the adults since the lung function instrument used by those subjects measured only FEV 1 and PEF. The absence of a significant association between PM and PEF in COPD subjects may be a function of disease process, ie, subjects with moderate COPD may have difficulty with this effort-dependent maneuver. In these subjects, FEV 1 appears to be a more robust measure of effect than PEF. Antiinflammatory medications were prescribed for COPD subjects, which may also weaken the association between PM and lung function decrements in this group. And, in contrast to the pediatric study subjects, the adults not receiving antiinflammatory medications did not have pulmonary disease, so they are less likely to experience lung function changes as a result of PM exposure.
Decrements in MMEF were associated with increased PM 2.5 in the children with asthma. We noted consistent decrements in all spirometric measures (FEV 1 , MMEF, and PEF) only in children not prescribed antiinflammatory medications. Some children with asthma have small airway inflammation in response to extrinsic triggers. 13, 14 Therefore, we selected MMEF as a potentially more sensitive indicator of small airway function. Although our study found a statistically significant change in MMEF for outdoor and central site PM 2.5 that was not present for FEV 1 , our result may not be clinically meaningful due to the low ambient PM 2.5 levels experienced in this study.
MMEF and FEV 1 results supported our a priori hypothesis that asthmatic children who were receiving daily antiinflammatory medication would be less sensitive to pm 2.5 effects than asthmatic children who were not receiving such medication. The strongest interaction effect of antiinflammatory medication was observed for indoor, central site, and outdoor PM 2.5 associations with MMEF and 1-day lagged personal PM 2.5 and PEF. This finding is consistent with prior epidemiologic and controlled exposure studies of air pollution 20 -22 and a proinflammatory mechanism of air pollutant health effects. 23 Our earlier report 24 of an association between increase in exhaled nitric oxide (eNO) and outdoor, indoor, personal, and central site PM 2.5 in these same chil- dren supports a direct effect on pulmonary inflammation as a potential source of asthma exacerbation. Bronchodilator use was comparable between the two medication groups (Table 1) and was not associated with PM 2.5 exposure in either group (data not shown). It was beyond the scope of this study to evaluate whether antiinflammatory medication was clinically indicated for some of the subjects in the noantiinflammatory medication group. Thus, the possibility that the prescribed medications were not always adequate to control asthma exacerbations cannot be ruled out.
It is important to note that these effects were seen in an air shed, where PM 2.5 values are considerably below the Environmental Protection Agency (EPA) 24-h standard of 65 g/m 3 and slightly below the annual standard of 15 g/m 3 (Fig 1) . The finding of associations despite low PM mass concentrations suggests that particle number, specifically the contribution of ultrafine particles, is of consequence. This question is of considerable interest and is currently the subject of numerous studies. For example, a Helsinki, Finland study 9 reported high correlations between particle mass concentrations for PM 2.5 and particle number concentrations in the accumulation mode range (0.01 to 1 m; r ϭ 0.85) but weaker correlations between PM 2.5 and particle number concentrations in the ultrafine range (0.01 to 0.1 m; r ϭ 0.26). This study 9 reported consistent associations between accumulation mode particles and decrements in PEF among adult asthmatic subjects; while inverse associations with ultrafine particles and PEF were observed, they were not significant. The correlation between PM 2.5 and ultrafine particles is dependent in part on the proximity to the source of ultrafine particles. Measurements of ultrafine particles were not available for our study.
Concentrations of gaseous pollutants are highly correlated with PM. 4 In this study, for example, the correlation coefficients with local outdoor PM 2.5 were r ϭ 0.51 for NO 2 and r ϭ 0.70 for CO and with central site PM 2.5 were r ϭ 0.56 for NO 2 and r ϭ 0.77 for CO. These gases may be better surrogates than PM for exposure to certain air pollution sources such as traffic. 25 However, PM, NO 2 , and CO all come from mobile sources and wood smoke. Both CO and NO 2 were significantly (p Ͻ 0.05) but inconsistently associated with decrements in lung function in our study populations (data not shown). For example, gases were significantly associated at 1-day lags with decreased FEV 1 in non-COPD adults, and also associated with decrements in FEV 1 (NO 2 , CO) and MMEF (NO 2 ) in pediatric subjects. So, we cannot rule out that associations between the gases and lung function may be part of the PM effect. 26 Moreover, the within-subject variation of PM (daily PM exposure relative to that subject's session mean) was Ͻ 5 g/m 3 , which limits our ability to determine whether larger changes in PM may lead to more consistent or clinically meaningful decrements in lung function. Another exposure factor is temporal variation of PM among the years of study. The adult subjects with COPD were studied mainly from March to October 2000, and their average outdoor exposure was 9.2 Ϯ 5.1 g/m
3
. Whereas the children with asthma were all studied from November 2000 to May 2001, their average outdoor exposure was 11.3 Ϯ 6.4. Wintertime PM concentrations in year 1 in Seattle were below average due to relatively warm, wet, and windy weather. The daily average hours of stagnation were 8.8 in year 1 and 11.6 in year 2. 12 The absence of consistent associations between spirometric measures or lower respiratory symptoms (data not shown) and particulate exposure in this study, especially in adults, may be partially explained by the use of 24-h average PM 2.5 exposures rather than short-term or peak exposures. In a published study 22 in which an association with symptoms was observed for peak exposures (PM 10 ), increased odds ratios for both 8-h maximum and 24-h mean particulate exposures were also noted for subjects not receiving antiinflammatory medications. Our results contrast with earlier findings in Seattle that reported a robust association between both lung function 10 and symptoms and PM 2. 5 11,27 in children with asthma in Seattle. Symptoms reported frequently do not correlate with FEV 1 28 or other markers of pulmonary effects such as eNO. 29 A study 30 that describes reporting of asthma symptoms by young (7-to 10-year-old) children indicates they may not have accurate perceptions of their asthma status.
In this study, the most consistent effects across all lung function end points were observed for indoor exposures. The composition of indoor PM may include allergens from both indoor and outdoor sources, endotoxin, and fine particles of outdoor origin that penetrate indoors, as well as particles that are generated indoors from cooking, vacuuming, and personal activities. Outdoor-generated particles accounted for an average of 81% (range, 54 to 100%) of indoor particles measured in the homes of eight children in this study. 31 In a recent article, 32 we described the lack of associations of eNO in these children with particles of indoor origin.
Our study has a number of strengths that add to the validity of our findings. These include residential level PM exposures, repeated measures on the same individual, and inclusion of medication and asthma history of the participants. Despite these strengths, our study had limitations. These include the small range and absolute level of PM exposure, the small number of participants in the study, the 24-h averaging time of PM, and the absence of aeroallergen measurements.
This study found consistent decrements in MMEF in children with asthma who were not receiving antiinflammatory medications. These findings suggest the need for future larger studies of PM effects in this susceptible population that repeatedly measure spirometry to include MMEF and potentially more sensitive markers of airway inflammation (eg, biomarkers of effect in exhaled breath condensate, and eNO). These future studies should also better assess the interaction of allergens on these PMinduced airway effects.
